Date	Headline
Feb 19, 2019	Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
Feb 12, 2019	PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
Jan 29, 2019	ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
Dec 06, 2018	PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
Nov 14, 2018	PROVECTUS BIOPHARMACEUTICALS PROVIDES DRUG DEVELOPMENT UPDATE FOR IMMUNO-DERMATOLOGY ASSET PH-10

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
Nov 08, 2018	10-Q	Quarterly report	html pdf xbrl
Aug 07, 2018	10-Q	Quarterly report	html pdf xbrl
May 09, 2018	10-Q	Quarterly report	html pdf xbrl
Mar 23, 2018	10-K	Annual report	html pdf xbrl
Nov 08, 2017	10-Q	Quarterly report	html pdf xbrl

Company Overview